Objective: Compared with HIV monoinfection, HIV dual infection has been associated with decreased CD4 þ T-cell counts and increased viral loads. The same markers are also associated with the development of HIV-associated neurocognitive disorder (HAND), which continues to be a prevalent problem in the era of combination antiretroviral therapy (ART). We sought to determine the relationship between dual infection and HAND.
Introduction
HIV-1 dual infection occurs when an individual is infected by two viral strains transmitted from different source partners [1] . Dual infection can be further classified as HIV-1 coinfection when both viruses are present at the outset of infection, or as HIV-1 superinfection when the second infection occurs after an a established immune response to the first. More than a decade has passed since the first cases of dual infection were described in humans [2] . Since that time, dual infection has been increasingly reported from several cohorts in large part because of improvements in amplification and sequencing technologies [3] [4] [5] . The incidence of superinfection has ranged between 1.44 and 4.96 per 100 person-years, comparable with the incidence of primary HIV infection depending on the cohorts studied and their associated risk factors [3] [4] [5] . The prevalence of dual infection in a large cohort of MSM in San Diego, California was 14.4% [3] . The importance of dual infection is demonstrated by its association with higher HIV viral load [6] [7] [8] [9] [10] and more rapid decline in the CD4 þ T-cell count [11, 12] . Despite these associations, few studies have investigated links between dual infection and end-organ damage.
A recent study of female sex workers in Kenya found that HIV-1 superinfection was associated with increased viral loads, but did not accelerate progression to AIDS or time to antiretroviral therapy (ART) initiation [10] . It remains unclear, however, if dual infection is associated with endorgan dysfunction, especially in the setting of ART. One organ system that can be interrogated for HIV-associated damage even among HIV-infected persons receiving ART is the central nervous system (CNS) by evaluating for HIV-associated neurocognitive disorder (HAND) [13] . Increasingly sensitive neuropsychological assessments that are standardized to normative control populations have allowed characterization of the spectrum of HAND. These sensitive assessments can detect neurocognitive impairment in the absence of clinical symptoms and have identified that the prevalence of HAND remains high even in the age of current ART [14] [15] [16] [17] . Although HAND and dual infection are both associated with markers of HIV disease progression and both occur more frequently, the relationship between dual infection and HAND has not been characterized. To address this, we applied deep sequencing to HIV DNA populations in blood samples collected from participants of the CNS HIV ART Effects Research (CHARTER) cohort to estimate the prevalence of dual infection and to compare dual infection with HAND.
Methods

Study participants and neuropsychological assessments
We retrospectively studied data and blood samples from 38 HIV-infected adults who had previously enrolled in the CHARTER cohort. CHARTER is an ongoing multisite, observational cohort study of HIV-infected adults whose initial assessment occurred between 2003 and 2010 [14] . For the present study, CHARTER participants were selected who had at least two longitudinal visits and were followed for more than 4 years, were more than 50 years of age at any study visit, received ART throughout follow-up, and had no confounding issues in neurocognitive assessments, like stroke or CNS opportunistic infections [13] . The age criterion was a requisite for the parent study, which investigated the virologic correlates of aging in a CHARTER subset; however, it provides the present study a sample that is representative of the aging HIVinfected US population. Written informed consent was obtained from all study participants. The study was approved by Human Subjects Protection Committees at each of the participating institutions.
As part of CHARTER, all participants had neurocognitive testing to assess seven neuropsychological domains as described previously [14] : verbal fluency, executive functions, speed of information processing, learning, delayed recall, working memory, and motor skills. Based on the testing, neurocognitive impairment was defined in accordance with the Frascati criteria for HAND [13] . Comorbid conditions that may contribute to HAND were classified as incidental (conditions that may affect neurocognitive performance to a minor degree but would be unlikely to cause an individual to be classified as impaired); contributing (conditions that could cause at least mild neurocognitive impairment, but did not confound attribution of impairment to HIV); or confounding (conditions that could fully explain impairment so that HIV effects could not be reliably inferred) [13, 14] . CHARTER participants with confounding comorbidities were excluded in this study.
DNA extraction and sequencing methods
Blood samples were collected at each study visit and HIV-1 DNA was isolated from peripheral blood mononuclear cell (QIAamp DNA Mini Kit; Qiagen, Germantown, Maryland, USA) and PAXgene tubes (PAXgene Blood DNA Kit; Qiagen) according to manufacturers' instructions. Four HIV coding regions, gag p24 (HXB2 coordinates 1366-1619), pol reverse transcriptase (RT, HXB2 coordinates 2708-3242), pol protease (PR, HXB2 coordinates 2253-2550), and env C2-V3 (HXB2 coordinates 6928-7344),were amplified by PCR with region-specific primers, and sequenced on 454 GS FLX Titanium and 454 Junior instruments (Roche, Branford, Connecticut, USA), as described previously [9, 18] .
Sequence analysis and dual infection confirmation
Sequence data were analyzed using the 454 Deep Sequencing bioinformatics pipeline, available as a part of the HyPhy software package and the Datamonkey web server (www.datamonkey.org/help/uds.php) [19, 20] . Briefly, high-quality reads were retained and aligned, and the maximum divergence was calculated for each coding region in sliding windows. dual infection was suggested when the maximum divergence exceeded previously established thresholds for each coding region [21] . Longitudinal viral sequence datasets from each participant were incorporated into a phylogeny along with a background of epidemiologically unrelated HIV sequences of the same subtype. If phylogenetic reconstruction suggested dual infection, sequences were checked for contamination against a database of all laboratory-generated viral sequences, and if none was found, the sample was resequenced to confirm dual infection [3] . Dual infection was confirmed when divergent viral lineages were present in longitudinal HIV sequences isolated from the same individual.
Statistical methods
Demographic and clinical characteristics were summarized and compared between the monoinfection and dual infection groups using independent samples t-test for continuous variables and Fisher's exact test for binary and categorical variables. The neurocognitive outcome was compared between monoinfection and dual infection groups using Fisher's exact test in unadjusted analyses. Unadjusted and adjusted comparisons between the two groups were summarized using odds ratios and 95% confidence intervals, based on the logistic regression likelihood ratio test. For the adjusted comparison multiple logistic regression was used. Covariates that were significant predictors of neurocognitive impairment at the 0.20 level using likelihood ratio test were candidates for the multiple logistic regression model; the covariate candidates included demographic (age, sex, ethnicity, years of education) clinical (CD4 þ T-cell count, viral load, estimated duration of infection, hepatitis C status, neurocognitive comorbidities)and behavioral (sexually transmitted infections, intravenous drug use) factors. These covariates were then included in a backward model selection procedure, in addition to mono versus dual infection groups, using a 0.20 threshold level. The likelihood ratio test was used for all covariates in the adjusted analysis. Two significant digits were used to report P values at least 0.1 and three digits if P less than 0.1. The study cohort was 87% men and the main HIV risk factor was sexual exposures (95%); 21 out of 38 reported being MSM as their main HIV risk factor (55%). The median age at the first study time point was 50 years (IQR: 45-53 years). Despite reporting ART use, 12 participants had a detectable plasma HIV viral load more than 500 copies/ml or more than 2.70 log 10 copies/ml, with a median plasma viral load of 4.02 log 10 copies/ml (IQR: 2.92-4.79 log 10 copies/ml). Characteristics for the study cohort are shown in Table 1 .
Results
Study cohort and HIV dual infection
Nine study participants (24%) had two discrete viral lineages observed across longitudinal time points and were categorized as having dual infection. Illustrative cases representing monoinfection and dual infection are shown in Fig. 1 . All participant infections were with HIV-1 subtype B. There were no significant differences in terms of plasma viral loads or CD4 þ T-cell counts at the baseline time point between those with monoinfection and dual infection; other characteristicsofthe monoinfection and dual infection groups are displayed in Table 1 . A higher frequency of intravenous drug use in the dual infection group was marginally significant (P ¼ 0.051).
detectable plasma and cerebrospinal fluid (CSF) viral loads were not associated with dual infection.
HIV-associated neurocognitive disorder and HIV dual infection
Neurocognitive impairment was assessed based on clinical ratings (global impairment) [14] . Assessment of neurocognitive impairment at the first study time point defined our nerocognitively impaired group. Global neurocognitive impairment was identified in 21 participants; 11 of these also had impairment at the second time point. Demographic and HIV disease characteristics among these impaired and normal groups are shown in Table 2 .
Significantly lower CD4 þ T-cell counts (both current and nadir) were associated with impairment (P ¼ 0.028 and P ¼ 0.043, respectively). There was no association between detectable plasma or CSF viral load and presence of neurocognitive impairment. Using clinical ratings, dual infection was not significantly associated with impairment; however, after adjusting for variables that were significantly predictive of impairment, multivariate analysis demonstrated a significant association between dual infection and HAND ( multivariable analysis because six participants had missing data, and the level in the remaining participants was undetectable in all but three. Important covariates, including hepatitis C, intravenous drug use, sexually transmitted infections (including syphilis), were not associated with either dual infection or neurocognitive impairment.
Discussion
The present study used deep sequencing of HIV DNA populations in blood to screen a well characterized cohort of individuals receiving ART for dual infection and found a high prevalence of dual infection (24%) among chronically infected individuals receiving ART, and an association between dual infection and HAND. These observations may provide a deeper understanding of the virologic correlates of HAND. Lentiviral dual infection has been described with feline immunodeficiency virus in cats, simian immunodeficiency virus in macaques and HIV-1 in chimpanzees [22] [23] [24] , so it is not surprising that HIV-1 dual infection occurs in humans. A recent domestic feline immunodeficiency virus study showed dual infection was associated with neuroinflammation and neurodegeneration, suggesting that infection by multiple viruses might contribute to neuropathogenesis [25] .
Whether the observed association between dual infection and HAND is causal cannot be determined by the current data. Neurocognitively impaired individuals may be more likely to become dually infected or both conditions may have a third causal condition in common. However, we did not find evidence linking both conditions with either intravenous drug use (associated with dual infection but not with neurocognitive impairment) or sexually transmitted infections (not associated with dual infection or neurocognitive impairment). The possibility that dual infection and neurocognitive impairment are causally linked is indirectly supported by the observations that HIV enters the CNS early in infection [26, 27] and that dual infection occurs most frequently in the first 1-2 years after primary HIV infection [3, 4] . Together, these events could lead to greater viral genetic diversity in the CNS, which might increase the risk of viral adaptation and fitness in the CNS.
The limitations of our analysis include its relatively small sample size, resulting in limited power to determine statistically significant associations with dual infection or HAND. Although a larger sample size would have increased power, our study had adequate power to test our primary hypothesis. Of note, the number of fully characterized dually infected participants worldwide stands at less than 70.
This study demonstrated the value of peripheral blood mononuclear cell DNA for deep sequencing studies of HIV dual infection, which is important as ART use limits dual infection studies using RNA from blood plasma. The current study identifies an interesting connection between dual infection and HAND, but the mechanisms underlying these associations remain unknown and require further investigation.
